Product Description
interferon, beta 1, fibroblast (IFNB1) Blocker
Mechanisms of Action: IFNB Agonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Belgium, Bulgaria, Canada, China, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Mexico, Poland, Slovakia, South Korea, Spain, Sweden, Taiwan, United States, Unknown Location
Active Clinical Trial Count: 13
Highest Development Phases
Phase 3: Dermatomyositis|Myositis|Polymyositis
Phase 2: Lupus Erythematosus, Cutaneous|Lupus Erythematosus, Systemic
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
C0251013 | P2 |
Unknown Status |
Lupus Erythematosus, Cutaneous|Lupus Erythematosus, Systemic |
2026-11-17 |
|
C0251006 | P3 |
Recruiting |
Dermatomyositis|Polymyositis |
2026-07-23 |
|
C0251013 | P2 |
Recruiting |
Lupus Erythematosus, Cutaneous|Lupus Erythematosus, Systemic |
2025-12-17 |
|
jRCT2031230382 | P3 |
Recruiting |
Myositis |
2025-12-04 |